Evidence map›Paper›PMID 30728224›Full record

ReviewDiabetes care2019

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.

Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode and 20 more

Registry-linked trialAbstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetes care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07325201 (Mitigating Diabetic Ketoacidosis in People With T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor), which is not on this map. Cited by 154 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07325201 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Mitigating Diabetic Ketoacidosis in People With T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation Into an Enhanced Glucose Ketone Report

TypeinterventionalSponsorHealthPartners InstituteRan2026 to 2030Enrolled80ConditionsType 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic KetoacidosisArmsSotagliflozin initiation
3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Thomas DanneDiabetes Centre for Children and Adolescents, Kinder- und Jugendkrankenhaus Auf der Bult, Hannover, Germany.ORCID 0000-0003-0773-6961
Satish GargUniversity of Colorado Denver and Barbara Davis Center for Diabetes, Aurora, CO.
Anne L PetersKeck School of Medicine of the University of Southern California, Los Angeles, CA.
John B BuseUniversity of North Carolina School of Medicine, Chapel Hill, NC.ORCID 0000-0002-9723-3876
Chantal MathieuDepartment of Endocrinology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium.ORCID 0000-0002-6099-2406
Jeremy H PettusDivision of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, San Diego, CA.ORCID 0000-0002-5999-0091
Charles M AlexanderAlexander Associates LLC, Gwynedd Valley, PA.
Tadej BattelinoDepartment of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Children's Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia.ORCID 0000-0002-0273-4732
F Javier Ampudia-BlascoClinic University Hospital of Valencia, Valencia, Spain.
Bruce W BodeAtlanta Diabetes Associates, Atlanta, GA.ORCID 0000-0002-9998-055X
Bertrand CariouClinique d'endocrinologie, L'institut du thorax, CHU Nantes, CIC 1413 INSERM, Nantes, France.ORCID 0000-0002-1580-8040
Kelly L CloseThe diaTribe Foundation, San Francisco, CA.
Paresh DandonaDivision of Endocrinology, Diabetes and Metabolism, University at Buffalo, The State University of New York, Buffalo, NY.ORCID 0000-0002-7055-2084
Sanjoy DuttaJDRF International, New York, NY.
Ele FerranniniNational Research Council (CNR) Institute of Clinical Physiology, Pisa, Italy.ORCID 0000-0002-1384-1584
Spiros FourlanosDepartment of Diabetes and Endocrinology, Royal Melbourne Hospital, Melbourne, Australia.ORCID 0000-0002-5153-8324
George GrunbergerGrunberger Diabetes Institute, Bloomfield Hills, MI.
Simon R HellerAcademic Unit of Diabetes, Endocrinology & Metabolism, University of Sheffield, Sheffield, U.K.ORCID 0000-0002-2425-9565
Robert R HenryDivision of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, San Diego, CA.ORCID 0000-0002-4821-0117
Martin J KurianClose Concerns, San Francisco, CA.
Jake A KushnerMcNair Interests, Houston, TX.ORCID 0000-0002-3646-1744
Tal OronJesse Z and Sara Lea Shafer Institute of Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Christopher G ParkinCGParkin Communications, Inc., Boulder City, NV chris@cgparkin.org.ORCID 0000-0001-6838-5355
Thomas R PieberDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Helena W RodbardEndocrine and Metabolic Consultants, Rockville, MD.ORCID 0000-0002-6187-8445
Desmond SchatzDivision of Endocrinology, Department of Pediatrics, University of Florida, Gainesville, FL.
Jay S SkylerDivision of Endocrinology, Diabetes and Metabolism, Miller School of Medicine, University of Miami, Miami, FL.
William V TamborlaneDepartment of Pediatrics, Yale School of Medicine, New Haven, CT.
Koutaro YokoteDepartment of Diabetes, Metabolism and Endocrinology, Chiba University Graduate School of Medicine, Chiba, Japan.ORCID 0000-0003-3033-4813
Moshe PhillipJesse Z and Sara Lea Shafer Institute of Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.ORCID 0000-0002-6616-5612

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR002489
6 · The paper itself

Abstract

Sodium-glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolute risk of diabetic ketoacidosis (DKA). Some cases presented with near-normal blood glucose levels or mild hyperglycemia, complicating the recognition/diagnosis of DKA and potentially delaying treatment. Several SGLT inhibitors are currently under review by the U.S. Food and Drug Administration and European regulatory agencies as adjuncts to insulin therapy in people with type 1 diabetes. Strategies must be developed and disseminated to the medical community to mitigate the associated DKA risk. This Consensus Report reviews current data regarding SGLT inhibitor use and provides recommendations to enhance the safety of SGLT inhibitors in people with type 1 diabetes.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic KetoacidosisSodium-Glucose Transporter 2 InhibitorsGlucoseHumansHypoglycemic AgentsRisk ManagementSodiumGlucoseHypoglycemic AgentsSodiumSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID30728224
PMCPMC6973545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.